pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2022-32-1-62-67pulmo-3513Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESЧисло эозинофилов как возможный предиктор определения степени тяжести одышки у пациентов с обострением хронической обструктивной болезни легкихEosinophil count can predict dyspnea level in patients with acute exacerbation of chronic obstructive pulmonary diseasehttps://orcid.org/0000-0003-3348-8375ЧекменБ.ÇekmenB.

Бора Чекмен – врач, доцент кафедры неотложной помощи, отделение неотложной медицинской помощи

78200, Карабюк, Шириневлер, Алпарслан, 1

тел.: (0090) 541-681-77-98

Bora Çekmen, MD, Аssociate Professor

Şirinevler, Alparslan Cd. No.1, 78200, Karabük

tel.: (0090) 541-681-77-98

ebrosrian@gmail.comhttps://orcid.org/0000-0002-1546-4612БилдикБ.BildikB.

Бушра Билдик – врач скорой помощи

78200, Карабюк, Шириневлер, Алпарслан, 1

тел.: (0090) 532-605-47-36

Büşra Bildik, MD, Emergency Physician

Şirinevler, Alparslan Cd. No.1, 78200, Karabük

tel.: (0090) 532-605-47-36

drbusrabeyoglu@gmail.comhttps://orcid.org/0000-0002-5094-6000ЭмреАтиш Ш.EmreAtiş Ş.

Эмре Атиш Шереф – врач скорой помощи

33230, Мерсин, Корукент Мах. 96015, Шехир Хастанеси Джд.

тел.: (0090) 506-928-81-86

Emre Atiş Ş., MD, Emergency Physician

Korukent Mah. 96015, Şehir Hastanesi Cd, 33230, Mersin

tel.: (0090) 506-928-81-86

dremreatis@gmail.comhttps://orcid.org/0000-0001-7688-172XКаяН.KayaN.

Неше Кая – врач скорой помощи

34384, Стамбул, Каптан Паша, ССК Окмейданы Хст. № 25

тел.: (0090) 553-533-84-95

Neşe Kaya, MD, Emergency Physician

Kaptan Paşa, SSK Okmeydanı Hst. No.25, 34384, İstanbul

tel.: (0090) 553-533-84-95

nashekaya@gmail.comhttps://orcid.org/0000-0002-4195-2601БозанО.BozanÖ.

Онер Бозан – врач скорой помощи

34384, Стамбул, Каптан Паша, ССК Окмейданы Хст. № 25

тел.: (0090) 505-512-15-00

Öner Bozan, MD, Emergency Physician

Kaptan Paşa, SSK Okmeydanı Hst. No.25, 34384, İstanbul

tel.: (0090) 505-512-15-00

onerbozan@gmail.comhttps://orcid.org/0000-0002-5800-0201КалканА.KalkanA.

Асим Калкан – врач, доцент кафедры неотложной помощи

34384, Стамбул, Каптан Паша, ССК Окмейданы Хст. № 25

тел.: (0090) 533-737-09-34

Asım Kalkan, MD, Аssociate Professor, Emergency Department

Kaptan Paşa, SSK Okmeydanı Hst. No.25, 34384, İstanbul

tel.: (0090) 533-737-09-34

drasimkalkan@hotmail.comОтделение неотложной медицинской помощи Учебно-исследовательской больницы Карабюкского университетаТурцияDepartment of Emergency Medicine, Karabuk University Training and Research HospitalTurkeyОтделение неотложной медицинской помощи городской больницы МерсинаТурцияDepartment of Emergency Medicine, Mersin City HospitalTurkeyОтделение неотложной медицинской помощи, Городская больница имени профессора Джемила ТасджиоглуТурцияDepartment of Emergency Medicine, Prof. Dr. Cemil Tascioglu City HospitalTurkey2022210220223216267Copyright © Чекмен Б., Билдик Б., Эмре А., Кая Н., Бозан О., Калкан А., 20222022Чекмен Б., Билдик Б., Эмре А., Кая Н., Бозан О., Калкан А.Çekmen B., Bildik B., Emre A., Kaya N., Bozan Ö., Kalkan A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3513

Число эозинофилов в крови уже используется в качестве биомаркера эозинофильного воспаления дыхательных путей. Эозинофилы обнаруживаются в дыхательных путях, тканях и крови во время стабилизации заболевания или обострений хронической обструктивной болезни легких (ХОБЛ). Полезными и проверенными новыми инструментами для оценки этих аспектов ХОБЛ являются модифицированная шкала одышки Комитета медицинских исследований (The modified Medical Research Council dyspnea scale – mMRC) и оценочный тест по ХОБЛ (COPD Assessment Test – CAT). Целью перекрестного исследования явилось изучение связи числа эозинофилов в крови с результатом оценки с помощью указанных шкал и количеством госпитализаций в отделение неотложной помощи у пациентов с обострениями ХОБЛ. Материалы и методы. Пациенты с ХОБЛ (n = 166: 126 (75,9 %) мужчин; средний возраст – 69,0 года) были распределены в 2 группы – в 1-ю группу вошли больные ХОБЛ, число эозинофилов у которых составило < 300 клеток / мкл–1, 2-ю – ≥ 300 клеток / мкл–1. В обеих группах проанализирована взаимосвязь между обострениями и числом госпитализаций в отделения неотложной помощи за последний год, оценкой по CAT и mMRC и сопутствующими заболеваниями. Результаты. У пациентов с более высоким числом эозинофилов отмечено меньшее количество госпитализаций по сравнению с таковым при низком уровне эозинофилов (5 и 10 соответственно); установлена также значимо более высокая средняя оценка по mMRC у пациентов с низким числом эозинофилов по сравнению с таковой у лиц с высоким числом эозинофилов (p = 0,022). Разница средней оценки по CAT между группами не являлась статистически значимой. Выявлена статистически значимая отрицательная взаимосвязь между числом эозинофилов и оценками по mMRC (r = –0,219, p = 0,005). Заключение. Установлено, что у пациентов с обострениями ХОБЛ и высоким числом эозинофилов показатель по mMRC обычно низкий. Кроме того, такие больные реже госпитализируются в отделения неотложной помощи, хотя это различие не являлось статистически значимым.

Blood eosinophil count is associated with measurements have been used as biomarkers for eosinophil-related airway inflammation. Eosinophils are found in the airways, tissues, and blood during stable disease or acute exacerbations of COPD (AECOPD). The modified Medical Research Council dyspnea scale (mMRC) and COPD assessment test (CAT) scores have been shown to be useful as novel tools for evaluating these aspects of COPD.The aim. This study aimed to investigate the relation of blood eosinophil count with the assessment scales and the number of emergency department (ED) admissions in patients with acute exacerbations COPD. Study Design. Cross-Sectional Study. Methods. Based on eosinophil count, the patients were divided into two groups: < 300 cells μL−1 and ≥ 300 cells μL−1. For these two groups, the relationship between acute exacerbation and the number of admissions to ED, the number of hospitalizations in the last one year, CAT score, mMRC score, and comorbid diseases were analyzed. Results. 166 patients was mean age 69.0, 126 (75.9%) male. Patients with high eosinophil count had fewer ED admission compared with those with low eosinophil count(5 and 10, respectively), Median mMRC score of patients with low eosinophil count was significantly higher compared with that of patients with high eosinophil count(p = 0.022).The difference between the median CAT scores of the two groups was not statistically significant. A statistically significant, negative relationship was found between the eosinophil count and mMRC scores (r = −0.219; p = 0.005). Conclusion. High levels of eosinophilia in patients presenting with AECOPD are associated with low mMRC score. Also, although not statistically significant, the number of admissions to the ED may be lower.

шкалы для оценки рискахроническая обструктивная болезнь легкиходышкаэозинофилыrisk scoreschronic obstructive pulmonary diseasedyspneaeosinophilsReferencesKerkhof M., Sonnappa S., Postma D.S. et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur. Respir. J. 2017; 50 (1): 1700761. DOI: 10.1183/13993003.00761-2017.Kerkhof M., Sonnappa S., Postma D.S. et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur. Respir. J. 2017; 50 (1): 1700761. DOI: 10.1183/13993003.00761-2017.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention Of Chronic Obstructive Pulmonary Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL14Nov2018-WMS.pdfGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention Of Chronic Obstructive Pulmonary Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL14Nov2018-WMS.pdfBafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184 (6): 662–671. DOI: 10.1164/rccm.201104-0597OC.Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184 (6): 662–671. DOI: 10.1164/rccm.201104-0597OC.Stockley R.A., Halpin D.M.G., Celli B.R., Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am. J. Respir. Crit. Care Med. 2019; 199 (10): 1195–1204. DOI: 10.1164/rccm.201810-1860SO.Stockley R.A., Halpin D.M.G., Celli B.R., Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am. J. Respir. Crit. Care Med. 2019; 199 (10): 1195–1204. DOI: 10.1164/rccm.201810-1860SO.Gao P., Zhang J., He X. et al. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2013; 8 (5): e57678. DOI: 10.1371/journal.pone.0057678.Gao P., Zhang J., He X. et al. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2013; 8 (5): e57678. DOI: 10.1371/journal.pone.0057678.Negewo N.A., McDonald V.M., Baines K.J. et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 1495–1504. DOI: 10.2147/COPD.S100338.Negewo N.A., McDonald V.M., Baines K.J. et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 1495–1504. DOI: 10.2147/COPD.S100338.Kolsum U., Donaldson G.C., Singh R. et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res. 2017; 18 (1): 88. DOI: 10.1186/s12931-017-0570-5.Kolsum U., Donaldson G.C., Singh R. et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res. 2017; 18 (1): 88. DOI: 10.1186/s12931-017-0570-5.Vedel-Krogh S., Nielsen S.F., Lange P. et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The Copenhagen General Population Study. Am. Respir. Crit. Care Med. 2016; 193 (9): 965–974. DOI: 10.1164/rccm.201509-1869OC.Vedel-Krogh S., Nielsen S.F., Lange P. et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The Copenhagen General Population Study. Am. Respir. Crit. Care Med. 2016; 193 (9): 965–974. DOI: 10.1164/rccm.201509-1869OC.Pascoe S., Locantore N., Dransfield M.T. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435–442. DOI: 10.1016/s2213-2600(15)00106-x.Pascoe S., Locantore N., Dransfield M.T. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435–442. DOI: 10.1016/s2213-2600(15)00106-x.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125. DOI: 10.1136/thoraxjnl-2015-207021.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125. DOI: 10.1136/thoraxjnl-2015-207021.Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014; 44 (6): 1697–1700. DOI: 10.1183/09031936.00162414.Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014; 44 (6): 1697–1700. DOI: 10.1183/09031936.00162414.Camargo L.A., Pereira C.A. Dyspnea in COPD: beyond the modified Medical Research Council scale. J. Bras. Pneumol. 2010; 36 (5): 571–578. DOI: 10.1590/s1806-37132010000500008.Camargo L.A., Pereira C.A. Dyspnea in COPD: beyond the modified Medical Research Council scale. J. Bras. Pneumol. 2010; 36 (5): 571–578. DOI: 10.1590/s1806-37132010000500008.Dodd J.W., Hogg L., Nolan J. et al. The COPD Assessment Test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011; 66 (5): 425–429. DOI: 10.1136/thx.2010.156372.Dodd J.W., Hogg L., Nolan J. et al. The COPD Assessment Test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011; 66 (5): 425–429. DOI: 10.1136/thx.2010.156372.Cheng S.L., Lin C.H., Wang C.C. et al. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients. J. Formos. Med. Assoc. 2019; 118 (1, Pt 3): 429–435. DOI: 10.1016/j.jfma.2018.06.018.Cheng S.L., Lin C.H., Wang C.C. et al. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients. J. Formos. Med. Assoc. 2019; 118 (1, Pt 3): 429–435. DOI: 10.1016/j.jfma.2018.06.018.Mahler D.A., Waterman L.A., Ward J. et al. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007; 132 (4): 1283–1290. DOI: 10.1378/chest.07-0703.Mahler D.A., Waterman L.A., Ward J. et al. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007; 132 (4): 1283–1290. DOI: 10.1378/chest.07-0703.Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 248–254. DOI: 10.1183/09031936.00102509.Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 248–254. DOI: 10.1183/09031936.00102509.Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54 (7): 581–586. DOI: 10.1136/thx.54.7.581.Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54 (7): 581–586. DOI: 10.1136/thx.54.7.581.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORTver1.0wms.pdfGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORTver1.0wms.pdfPapi A., Romagnoli M., Baraldo S. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162 (5): 1773–1777. DOI: 10.1164/ajrccm.162.5.9910112.Papi A., Romagnoli M., Baraldo S. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162 (5): 1773–1777. DOI: 10.1164/ajrccm.162.5.9910112.Brusselle G., Pavord I.D., Landis S. et al. Blood eosinophil levels as a biomarker in COPD. Respir. Med. 2018; 138: 21–31. DOI: 10.1016/j.rmed.2018.03.016.Brusselle G., Pavord I.D., Landis S. et al. Blood eosinophil levels as a biomarker in COPD. Respir. Med. 2018; 138: 21–31. DOI: 10.1016/j.rmed.2018.03.016.Jabarkhil A., Moberg M., Janner J. et al. Elevated blood eosinophils in acute COPD exacerbations: better short- and longterm prognosis. Eur. Clin. Respir. J. 2020; 7 (1): 1757274. DOI: 10.1080/20018525.2020.1757274.Jabarkhil A., Moberg M., Janner J. et al. Elevated blood eosinophils in acute COPD exacerbations: better short- and longterm prognosis. Eur. Clin. Respir. J. 2020; 7 (1): 1757274. DOI: 10.1080/20018525.2020.1757274.Casanova C., Celli B.R., de-Torres J.P. et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur. Respir. J. 2017; 50 (5): 1701162. DOI: 10.1183/13993003.01162-2017.Casanova C., Celli B.R., de-Torres J.P. et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur. Respir. J. 2017; 50 (5): 1701162. DOI: 10.1183/13993003.01162-2017.Couillard S., Larivée P., Courteau J., Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017; 151 (2): 366–373. DOI: 10.1016/j.chest.2016.10.003.Couillard S., Larivée P., Courteau J., Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017; 151 (2): 366–373. DOI: 10.1016/j.chest.2016.10.003.Duman D., Aksoy E., Agca M.C. et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2469–2478. DOI: 10.2147/COPD.S90330.Duman D., Aksoy E., Agca M.C. et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2469–2478. DOI: 10.2147/COPD.S90330.Ulaşlı S.S., Ünlü M. [New concept in the classification of chronic obstructive pulmonary disease severity]. Güncel Göğüs Hastalıkları Serisi. 2013; 1 (1): 13–19. Available at: http://ghs.asyod.org/Dosyalar/GHS/2013/1/3d84ce94-f9f1-4276-877b-6e5381ce0abc.pdf (in Turkish).Ulaşlı S.S., Ünlü M. [New concept in the classification of chronic obstructive pulmonary disease severity]. Güncel Göğüs Hastalıkları Serisi. 2013; 1 (1): 13–19. Available at: http://ghs.asyod.org/Dosyalar/GHS/2013/1/3d84ce94-f9f1-4276-877b-6e5381ce0abc.pdf (in Turkish).Zhou A., Zhou Z., Peng Y. et al. The role of CAT in evaluating the response to treatment of patients with AECOPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2849–2858. DOI: 10.2147/COPD.S175085.Zhou A., Zhou Z., Peng Y. et al. The role of CAT in evaluating the response to treatment of patients with AECOPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2849–2858. DOI: 10.2147/COPD.S175085.

The authors declare that there are no conflicts of interest present.